Active Ingredient History

  • Now
Carboprost is an analogue of naturally occurring prostaglandin F2alpha. Administered intramuscularly carboprost stimulates in the gravid uterus myometrial contractions similar to labor contractions at the end of a full term pregnancy. It is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and for the treatment of postpartum hemorrhage due to uterine atony, which has not responded to conventional methods of management. The most frequent adverse reactions observed are related to its contractile effect on smooth muscle: vomiting, diarrhea, nausea, fever and flushing. Carboprost may augment the activity of other oxytocic agents. Concomitant use with other oxytocic agents is not recommended.   NCATS

  • SMILES: CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)O
  • Mol. Mass: 368.51
  • ALogP: 3.43
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$259.2210 - $317.3840
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (5z,9alpha,11beta,13e,15s)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oate | 15-methylprostaglandin f2alpha-tromethamine | (15s)-15-methyl-pgf2alpha tromethamine salt | 15(s)-15-methyl-pgf2alpha tromethamine salt | (15s)-15-methylprostaglandin f2alpha tromethamine | 15(s)-15-methylprostaglandin f2alpha tromethamine | carboprost | carboprost trometamol | carboprost trometanol | carboprost tromethamine | hemabate | methyldinoprost | prostin m-15 | u-32921 | u-32921e


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue